NEW DELHI: The Indian Patent Office has rejected the grant of a patent for dolutegravir , a crucial HIV drug marketed by Viiv Healthcare , facilitating the entry of generics and expanding access to affordable, life-saving treatment. The decision, announced after a contentious nearly decade-long battle, follows the company's patent application for the HIV treatment in 2007.
The company faced multiple pre-grant oppositions from Natco and various advocacy groups between 2013 and 2019, according to the order accessed by TOI. It led to the Patent Office rejecting the grant of a patent recently. Experts believe the ruling could serve as an example against the practice of " evergreening " patents, a practice that extends patent life through patenting of obvious forms and improvements of life-saving medicines. Over the next few years, with more players entering the market, the first-line HIV drug will likely be available at a fraction of the innovator price.
"I am of the opinion that claims are not patentable under Section 3(d) of the Act since no enhanced therapeutic efficacy has been demonstrated in the specification," the order by Deputy Controller D Usha Rao said.
Viiv Healthcare, which is majority owned by GSK and has Pfizer and Shionogi as major shareholders, is focused on HIV therapies. In April 2014, the Medicines Patent Pool and ViiV Healthcare signed licensing agreements to accelerate access to dolutegravir, for adult and paediatric care.
The company faced multiple pre-grant oppositions from Natco and various advocacy groups between 2013 and 2019, according to the order accessed by TOI. It led to the Patent Office rejecting the grant of a patent recently. Experts believe the ruling could serve as an example against the practice of " evergreening " patents, a practice that extends patent life through patenting of obvious forms and improvements of life-saving medicines. Over the next few years, with more players entering the market, the first-line HIV drug will likely be available at a fraction of the innovator price.
"I am of the opinion that claims are not patentable under Section 3(d) of the Act since no enhanced therapeutic efficacy has been demonstrated in the specification," the order by Deputy Controller D Usha Rao said.
Viiv Healthcare, which is majority owned by GSK and has Pfizer and Shionogi as major shareholders, is focused on HIV therapies. In April 2014, the Medicines Patent Pool and ViiV Healthcare signed licensing agreements to accelerate access to dolutegravir, for adult and paediatric care.
You may also like
King Charles given adorable nickname by children of Queen Camilla's son who think he's 'wonderful'
Canada using a routine NIA post to link India to goon's killing in Winnipeg
Fuzzy Logic: Can The Problem Of Urban Apathy Towards Voting Be Solved?
Embrace Confidence: Feel Comfortable In Your Own Skin
Editorial: Diplomacy Is A Must To End Disputes
Sharad Purnima 2024: Donate THESE Things On This Day To Get Auspicious Results
Hundreds of "mysterious black balls" wash ashore on popular Sydney beach
Guiding Light: Sharad Navaratri
Editorial: Democracy, The Key To Prosperity
Delhi-Chicago flight diverted to Canada as bomb hoaxes disrupt operations for 2nd day
Cristiano Ronaldo left furious as Andy Robertson breaths partial sigh of relief
Did an impending deposition spur Trudeau sabre-rattling?
'Opportunity Agenda For Black Men': All About Kamala Harris' New Economic Plan
Terrorists based in US & Canada behind killing of Shaurya Chakra winner in Punjab, NIA tells SC
10 killed, 15 injured in Israeli airstrike on Lebanon: Ministry
British Indians most successful ethnic group in UK: report
Shops shut, tight vigil in Bahraich; 52 arsonists held
Blackpink's Lisa Turns Up The Heat With ROCKSTAR And Moonlit Floor, Struts Her Stuff At Victoria's Secret Fashion Show
Remove toilet limescale using 3-item natural cleaner - no bleach or hard scrubbing needed
Only the very cleverest can find the goat among the herd of sheep in less than a minute